Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nadunolimab (CAN04) in solid tumors
NCT03267316Phase 2Completed
- Sponsor
- Cantargia AB
- Start
- Sep 2017
- Primary completion
- Mar 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of nadunolimab in non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), triple-negative breast cancer (TNBC), colorectal cancer (CRC), sponsored by Cantargia AB. Started Sep 2017; status: completed.
02
Drugs
nadunolimab
03
Conditions
non-small cell lung cancer (NSCLC)pancreatic ductal adenocarcinoma (PDAC)triple-negative breast cancer (TNBC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03267316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03267316.